vs
Side-by-side financial comparison of BioRestorative Therapies, Inc. (BRTX) and Charming Medical Ltd (MCTA). Click either name above to swap in a different company.
BioRestorative Therapies, Inc. is a clinical-stage biotechnology company focused on developing innovative regenerative medicine therapies. Its core pipeline includes candidate treatments for chronic lower back pain, metabolic disorders and other unmet medical needs, primarily serving markets in North America as it advances novel cell-based therapeutic candidates through clinical trials.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
Revenue
BRTX
MCTA
| Q4 25 | $19.6K | — | ||
| Q3 25 | $11.8K | — | ||
| Q2 25 | $303.3K | — | ||
| Q1 25 | $25.0K | — | ||
| Q4 24 | $43.3K | — | ||
| Q3 24 | $233.6K | — | ||
| Q2 24 | $89.1K | — | ||
| Q1 24 | $35.0K | — |
Net ProfitBRTXMCTA
| Q4 25 | $-3.2M | — | ||
| Q3 25 | $-3.0M | — | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-5.3M | — | ||
| Q4 24 | $-1.6M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-4.0M | — | ||
| Q1 24 | $-2.2M | — |
Gross MarginBRTXMCTA
| Q4 25 | 91.7% | — | ||
| Q3 25 | 10.4% | — | ||
| Q2 25 | 97.1% | — | ||
| Q1 25 | 88.4% | — | ||
| Q4 24 | 92.3% | — | ||
| Q3 24 | 92.2% | — | ||
| Q2 24 | 92.7% | — | ||
| Q1 24 | 100.0% | — |
Operating MarginBRTXMCTA
| Q4 25 | -19516.8% | — | ||
| Q3 25 | -31432.3% | — | ||
| Q2 25 | -1089.8% | — | ||
| Q1 25 | -19230.1% | — | ||
| Q4 24 | -6212.8% | — | ||
| Q3 24 | -979.0% | — | ||
| Q2 24 | -2770.8% | — | ||
| Q1 24 | -11740.7% | — |
Net MarginBRTXMCTA
| Q4 25 | -16365.5% | — | ||
| Q3 25 | -25748.1% | — | ||
| Q2 25 | -875.8% | — | ||
| Q1 25 | -21359.2% | — | ||
| Q4 24 | -3778.6% | — | ||
| Q3 24 | -467.2% | — | ||
| Q2 24 | -4521.4% | — | ||
| Q1 24 | -6352.2% | — |
EPS (diluted)BRTXMCTA
| Q4 25 | $-0.31 | — | ||
| Q3 25 | $-0.33 | — | ||
| Q2 25 | $-0.30 | — | ||
| Q1 25 | $-0.64 | — | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.13 | — | ||
| Q2 24 | $-0.50 | — | ||
| Q1 24 | $-0.33 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
